Real-World Study Led by Observational and Pragmatic Research Institute Suggests GLP-1 Receptor Agonists May Reduce COPD Exacerbation Risk in Patients with Type 2 Diabetes

An international real-world study coordinated by the Observational and Pragmatic Research Institute (OPRI) suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with fewer exacerbations and reduced corticosteroid use in patients living with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D). The findings, published in Pragmatic and Observational Research, are based on data from a large UK primary care population.

COPD and T2D frequently coexist and contribute to a high burden of morbidity and healthcare utilisation. Although GLP-1 RAs are primarily used for metabolic control[JT1] , growing evidence indicates they may also influence respiratory outcomes. In this retrospective matched cohort study including 4,479 patients initiating GLP-1 RA therapy and matched controls, treatment initiation was associated with significantly fewer COPD exacerbations, fewer oral corticosteroid prescriptions, and lower hospital resource utilisation during 12 months of follow-up. 

“These results highlight the importance of exploring treatments beyond traditional respiratory therapies when managing patients with COPD and complex cardiometabolic comorbidities,” said Prof. Bernardino Alcázar-Navarrete, respiratory physician at the University of Granada and Hospital Universitario Virgen de las Nieves. “The study provides clinically meaningful real-world evidence suggesting that GLP-1 receptor agonists could potentially modify exacerbation risk, opening new avenues for integrated and personalised care strategies.”

Investigators note that the observed benefits may reflect anti-inflammatory mechanisms, weight reduction, or systemic metabolic effects, although causal conclusions cannot be drawn from observational data alone. The authors emphasise that prospective randomised clinical trials are needed to confirm whether GLP-1 RAs can play a disease-modifying role in COPD.

The study was led by OPRI with contributions from an international network of academic partners across Europe, Canada, and Asia, reinforcing the growing interest in multidisciplinary approaches to cardiometabolic and respiratory multimorbidity.

To view read the full publication in the Prag Obs Res.